Search
Font size
- 1 2 3 + Font size

click to adjust

Page tools
Grants for Targets
Clinical Trials
tagcould

News


01/25/10, Hemophillia Bayer to Discontinue Phase II Clinical Trial for Long-Acting Recombinant Factor VIII Following Interim Analysis Study will not be able to meet primary endpoint / Bayer remains committed to developing its long-acting recombinant factor VIII compounds; alternative candidates in development more

IMI-Logo IMI – Innovative Medicines Initiative SAFE-T Project: researchers search for biomarkers to improve the early detection of drug-induced organ damage more  

http://bayerscheringpharma.de/scripts/pages/en/index.php

Copyright © Bayer Schering Pharma AG